Dipyridamole Tablets

It has anti-thrombotic effects. Dipyridamole inhibits platelet aggregation, and high concentrations (50 μg/ml) can inhibit platelet release. The mechanism of action may be (1) inhibiting the uptake of adenosine by platelets, epithelial cells and red blood cells. At therapeutic concentrations (0.5-1.9 μg/dl), the inhibitory effect is dose-dependent. The local adenosine concentration increases, acting on the A2 receptors of platelets, stimulating adenylate cyclase, and increasing cyclic adenosine monophosphate (cAMP) in platelets. Through this pathway, platelet aggregation caused by stimulation such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP) is inhibited. (2) Inhibiting phosphodiesterase (PDE) in various tissues. The therapeutic concentration inhibits cyclic guanosine monophosphate phosphodiesterase (cGMP-PDE), and the inhibitory effect on cAMP-PDE is weak, thereby enhancing the increase in cGMP concentration caused by endothelial relaxing factor (EDRF). (3) Inhibits the formation of thromboxane A2 (TXA2), which is a potent agonist of platelet activity. (4) Enhances the effect of endogenous PGI2. Dipyridamole has a vasodilatory effect. Intraduodenal administration of dipyridamole to dogs produced dose-related decreases in systemic and coronary vascular resistance, lowered systemic blood pressure, and increased coronary blood flow. The effect took effect 24 minutes after administration and lasted for about 3 hours. The same hemodynamic effects were observed in humans. However, acute intravenous administration can reduce local myocardial perfusion distal to the stenotic coronary artery. In 111-week oral studies in mice and 128-142-week oral studies in rats, 8, 25, and 75 mg/kg (1, 3.1, and 9.4 times the maximum recommended daily dose for humans) of dipyridamole did not produce significant carcinogenic effects. The results of the mutagenicity test were negative. The rat reproduction test used 60 times the maximum recommended daily dose of dipyridamole for humans and showed no evidence of reproductive damage. However, at 115 times the maximum recommended daily dose for humans, the number of corpora lutea was significantly reduced and live fetal implantation was reduced. Tests on mice, rats and rabbits did not show evidence that dipyridamole harmed the fetus. The oral LD50 for mice was 2150 mg/kg; the single oral lethal dose was 6000 mg/kg in rats and 350 mg/kg in dogs.

The main ingredient of this product is dipyridamole.

This product is a sugar-coated tablet, which appears yellow after removing the sugar coating.

Used for thromboembolic diseases and ischemic heart disease.

Oral administration: 25-50 mg (1-2 tablets) at a time, 3 times a day, before meals. Or as directed by a doctor.

Adverse reactions are mild and short-lived at therapeutic doses, and most of the initial side effects disappear after long-term use. Common adverse reactions include dizziness, headache, vomiting, diarrhea, flushing, rash and itching, and rarely angina and liver dysfunction. It is rare for adverse reactions to persist or be intolerable, and they can be eliminated by stopping the drug. In post-marketing experience reports, rare adverse reactions include laryngeal edema, fatigue, discomfort, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, alopecia, cholelithiasis, palpitations and tachycardia.

Contraindicated for allergy sufferers.

Precautions for children: Precautions for pregnancy and lactation: Precautions for the elderly:

(1) It has a synergistic effect with aspirin. When used in combination with aspirin, the dose can be reduced to 100-200 mg per day. (2) When this product is used together with dicoumarol anticoagulants, bleeding does not increase or worsen.

Keep away from light and store in a sealed container.

25 mg

24 months.

Shenyang Red Flag Pharmaceutical Co., Ltd.

• Founded in:

  1998-10-30

• Address:

  No. 6 Xinluo Street, Hunnan New District, Shenyang

• Tax NO.:

  912101121178724277

• Registered Funds:

  100 million yuan

• Website:

  Log in to view

• Email:

  Log in to view